American Shared Hospital Services (AMS) Earnings Call Transcript & Summary

August 14, 2023

NYSE American US Health Care Health Care Providers and Services earnings 60 min

Earnings Call Speaker Segments

Stephanie Prince

executive
#1

Thanks, Allison, and I appreciate all of you being with us today. We put out AMS' Q2 2023 earnings press release this morning ahead of market open. Should you require one, you'll find it on the company's site, ashs.com, under the Investors tab in Press Releases. Prior to handing the call to management, I'd like to offer a few comments regarding forward-looking statements. Kindly be aware that a number of things we might say during this conference call regarding the company's future expectations, plans and prospects are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. As a consequence of a number of significant factors, among them those covered in the company's SEC filings, actual results could differ materially from what those forward-looking statements indicate; this takes in the company's quarterly report on Form 10-Q covering the 3-month period that concluded March 31, 2023, the annual report on Form 10-K covering the year that concluded December 31, 2022, and the definitive proxy statement for the Annual Meeting of Shareholders convened on June 20, 2023. No obligation is assumed by the company to update the information in this conference call. At this point I'd like to pass the call to Ray Stachowiak, Executive Chairman of AMS. Ray?

Ray Stachowiak

executive
#2

Thanks, Stephanie, and good afternoon to all of you. We appreciate your joining us today for the earnings conference call covering our second quarter of 2023. Some opening remarks from me will come first, after which I'll hand things over to Peter Gaccione, who serves as Chief Executive Officer of AMS. Our CFO, Bob Hiatt, will follow with a financial review covering the second quarter's results. Once those prepared remarks are finished, we'll take your questions. AMS delivered a good second quarter, with revenue rising almost 11% year over year to $5.6 million. Compared with the $4.9 million recorded in this year's first quarter, revenue also grew just over 13%. Solid cost controls helped push the gross margin up almost 21%, to $2.5 million, which equals 45.2% of revenue. That marks the highest level achieved since the fourth quarter of 2021. Throughout the quarter, our expanded sales and marketing team kept generating and pursuing many new business opportunities; we put roughly $250,000 into activities needed to chase 3 unique business opportunities that would broaden our domestic footprint. Beyond that, our team is pursuing several additional opportunities with current customers involving extensions of ongoing agreements and upgrades of products to newer cancer treatment technologies. This morning we announced our third order of the year, covering an extension of an upgrade to a new Esprit Gamma Knife with Methodist Hospital in San Antonio, Texas. That said, while reviewing our existing sites, we identified 2 that aren't considering renewing their agreements. As a result, we've now added $578,000 to our reserves for impaired assets and anticipated removal costs should that happen. Discussions with both sites about other alternatives are underway, but we judged it prudent to raise these reserves at this time. Excluding these 2 items, which together came to $828,000, net income would have been approximately $340,000 higher, at roughly $232,000, or $0.04 per share, versus the $188,000, or $0.03 per share, reported in our first quarter; we're very excited about new equipment installations featuring expanded treatment offerings at our 3 international locations. At our newest cancer center joint venture in Puebla, Mexico, a digital linear accelerator with VMAT, IGRT and radiosurgery capability, or LINAC, is in its final installation phase and, once completed, will be the most advanced radiation therapy treatment system within our catchment area. Patient treatments should begin there in November. At our center in Ecuador, installation of the upgraded Gamma Knife ICON is expected to start in September, with patient treatments expected to restart in November 2023. In Peru, we expect installation of the new Gamma Knife Esprit to begin during quarter 1 2024. Once installation is complete, it will be the only Esprit Gamma Knife in the country for noninvasive radiosurgery and one of the first Esprit systems anywhere in South America. Please note that when treatments start up in November, the Puebla, Mexico joint venture will become a new revenue stream. For the duration of each installation, no patients will be seen in Ecuador or Peru. Once those installations wrap up, the 3 centers we operate will hold the most advanced radiotherapy cancer treatment systems available in each of those markets. We're eager to bring broader treatment options to the numerous patients in those regions, and we anticipate growth in our international revenue. Even with heavier investment levels, we kept producing positive cash flow in the second quarter and once again grew our cash balances, which stand at $13.8 million now, equal to roughly $2.18 per share. As our cash balance grows, interest income from it is also assisting in offsetting the greater interest expense tied to our variable rate debt. To wrap up my remarks, I'd say this is an exciting moment for AMS following all the repositioning we've carried out over the last 3 years. Our activity levels are up considerably, and we're eager to share our results with you in the months ahead. At this point I'll hand the call over to Peter.

Peter Gaccione

executive
#3

Thank you, Ray, and good afternoon to all of you. Since the previous call, we have stayed quite busy, and with more resources being committed each quarter, multiple opportunities keep flowing into our sales pipeline. Several factors explain that expansion, among them the highly seasoned sales and marketing group assembled during the last year. This team, myself included, is widely recognized by numerous individuals involved on both the provider and the customer side of our field, something that matters enormously in the cancer care sector. A bigger, more veteran team, along with its expanding footprint at major industry trade shows and events, has likewise raised awareness of our company and the services it offers among key opinion leaders in radiation oncology, in radiosurgery, and among other important decision makers throughout the cancer care arena. That visibility will grow even more once our team shows up at ASTRO — the annual meeting of the American Society for Radiation Oncology, held this October in San Diego, California. For the first time ever, AMS will have a booth at the ASTRO trade show, the biggest international trade show in radiation oncology, and we anticipate that our presence there will generate further sales leads, plus productive in-person meetings with numerous key OEM strategic partners of ours who likewise attend ASTRO. Beyond that, we intend to participate in other relevant annual and regional gatherings in radiation oncology and radiosurgery too. Additionally, we just rolled out a fresh website and social media footprint for GK Financing, or GKF, a subsidiary of AMS that has existed for a long time and where Elekta serves as our strategic partner. GKF ranks among the world's foremost suppliers of Gamma Knife radiosurgery products and services, delivering inventive financial and turnkey solutions. Within our industry niche, GKF stands alone as the only third-party finance company aligned with a major OEM. And never before have we elevated and showcased GKF and what it can do so directly and specifically. It pleases us to report that Gamma Knife procedures rose by more than 5% compared with the first quarter of the year; we attribute that largely to our in-house customer advocate, who came aboard only a few months back. Ranjit has concentrated on boosting Gamma Knife utilization across all of our Gamma Knife sites. An element of our customer advocate's review involves consistently examining how every one of our Gamma Knife sites is performing and engaging the lowest-volume sites, passing along best practices and exploring ways we can collaborate to lift patient volumes. To illustrate, among the 3 lowest sites from the prior quarter, 2 have increased volume thus far, and with 1 of them we lengthened our relationship by locking in a lease agreement extension through year 2037, along with our second order this year. That order covers an upgrade to the Leksell Gamma Knife Esprit featuring a new source, with installation set for September 2023. Today we shared that we've received our third order this year, which again comes from a current client, for a new Esprit set to be installed before this year is over. With enhanced capabilities, the Esprit represents Elekta's newest offering, and once these 2 units are in place, they'll be part of the first 10 Esprits installed across the U.S. The initial order we told you about several months back finished installation not long ago and began treating patients earlier in this month. We've gained solid traction quickly, and while it's still early, I take great pride in our progress to this point and in what I think we can achieve ahead. At this point I'll hand things over to Bob to walk through the financials.

Bob Hiatt

executive
#4

Thanks, Peter, and good afternoon to all of you. Revenue for the second quarter rose 10.6%, reaching $5.6 million, up from $5 million during the same period last year. Domestically, revenue climbed 16.2% to $4.8 million, while international revenue came in at $756,000, versus $894,000 a year earlier — a decline of 15.4%. For the proton therapy system in Florida, second quarter revenue grew 10.3% to $2.5 million, compared with $2.3 million, mainly because average reimbursement was higher period-over-period in the current quarter. Proton therapy fractions totaled 1,370 in the second quarter, which is up 3.5%, or 46 fractions. Gamma Knife revenue overall rose 10.9% to $3 million. The Gamma Knife segment's total gain resulted primarily from increased average reimbursement, which was partially counterbalanced by a lower volume of procedures. That rise in average reimbursement continues to stem from a beneficial payer mix change, with a greater proportion coming from commercial payers. During 2023's second quarter, Gamma Knife procedure count reached 309, compared with 335 during the equivalent period last year — a decline of 26 procedures, or 7.8%, a movement consistent with ordinary cyclical variation. For the second quarter of 2023, gross margin climbed 20.6%, reaching $2.5 million, equal to 45.2% of revenue, versus gross margin during 2022's second quarter of $2.1 million, or 41.5% of revenue. Selling and administrative costs climbed 73.5%, reaching $2 million in Q2, compared to $1.1 million during the same quarter last year. Within that number is approximately $250,000 that went toward chasing new business opportunities, which Ray mentioned, along with increased salaries tied to management and sales team hires brought on during the past year. Net interest expense came to $167,000 in the 2023 period, up from $149,000 in the comparable period a year earlier. The reason for that rise is a higher interest rate applied to the company's variable debt, though this was partly offset by greater interest income generated from the company's expanding cash balance. Compared with Q1 of this year, net interest expense saw improvement, driven by more interest income. For Q2 2023, we posted an operating loss of $325,000. In Q2 2022, by contrast, we had operating income of $793,000. The swing reflects increased selling and administrative costs, plus a $578,000 hit this period from writing down impaired assets and covering removal costs — there were no such write-downs a year earlier. On taxes, we booked a $35,000 benefit in Q2, whereas the same quarter last year brought $248,000 in income tax expense. That drop this period stems mainly from weaker earnings, return-to-provision adjustments tied to foreign tax returns, and permanent domestic tax differences. For American Shared Hospital Services, the second quarter of 2023 closed with a net loss of $111,000, equal to $0.02 per diluted share. In the same period of 2022, the company had net income of $497,000, or $0.08 per diluted share. As Ray noted, excluding two factors — higher outlays for new business investment and an increase in reserves — which together totaled $828,000, net income would have come in roughly $343,000 higher, at approximately $232,000, or $0.04 per diluted share, compared with the $497,000, or $0.08 per diluted share, reported for last year's corresponding quarter. During each period, the fully diluted weighted average count of common shares outstanding was roughly 6.3 million, which was basically unchanged. This period's adjusted EBITDA, a non-GAAP financial measure, hit $1.9 million, compared with $2.1 million in the second quarter of 2022. Cash, cash equivalents and restricted cash totaled $13.8 million as of June 30, 2023, an increase from $12.5 million as of December 31, 2022. At the end of the quarter, shareholders' equity, after excluding noncontrolling interests in subsidiaries, came to $21.9 million, or $3.52 per outstanding share, versus $21.6 million, or $3.50 per outstanding share, at June 30, 2022. That concludes the formal part of our presentation. We appreciate your joining us today. We're eager to share updates on our progress in the quarters to come. Operator, at this point we'd like to hand the call back to you and open things up for questions.

Tony Kamin

analyst
#5

For the first question, I'd like to ask about your pipeline. Could you give us some sense — any detail at all — regarding where things stand with, or what the chances are for, fresh discussions around proton beam?

Ray Stachowiak

executive
#6

Absolutely, Tony. It's Ray here. I appreciate the question; that's a really good one. The way I'd put it, and the way I can discuss what's in our pipeline without getting into too much detail — and I'm reluctant to get into too much detail — is that a little of everything we've spent roughly the past year or so discussing is represented in that pipeline; so what does that mean? We've discussed growing our offerings beyond solely Gamma Knives and Mevion proton beam systems, though Mevion photon beam systems remain part of it — actually, proton beam systems from whatever supplier. We don't favor any vendor. Other items, such as linear accelerators, sit in our pipeline, and with Puebla, Mexico, we've demonstrated that this is precisely what we're delivering in that instance. MR/LINACs are part of it as well, and chances for MR/LINACs are present in our pipeline. Another topic we've spent roughly the past year or so chatting about is the various business models available for us to present to the market. As you're aware, we're able to create many imaginative, adaptable financing structures for our clients; a joint venture is something we can do; and when it comes to our international operations, we can run our own centers where our own staff operates the equipment and we bill patients direct, rather than going via an intermediary or a health care system. We've also raised the idea of why we couldn't bring the business model we use internationally into the domestic marketplace. And I can tell you that even those chances are present in our pipeline.

Tony Kamin

analyst
#7

All right. Regarding the Esprit that you got a contract for, or that was announced today, could you — is there a notable difference in price when comparing the Esprit with the Perfexions?

Ray Stachowiak

executive
#8

Well, when it comes to the Perfexion, that's not something the OEM is right now making available to the market. As you're aware, OEMs aim to come out front with the newest and best technology they have, and the Esprit represents their newest and best technology along with their product offering.

Tony Kamin

analyst
#9

No, I’m only attempting to get clarity on whether this is your chance to install units that might secure better reimbursement, since they cost more or possess additional functions.

Ray Stachowiak

executive
#10

They do possess additional functions. And regarding what you asked, to give you a bit more detail on this, Peter, would you like to field that question and explain how the Esprit differs from the Perfexion, including some of those features?

Peter Gaccione

executive
#11

Absolutely, absolutely. Glad to do that. The main issue isn't really what we get reimbursed, since the therapies are fairly comparable — it's the extra clinical capabilities and advantages that Esprit brings compared with the Perfexion system. To illustrate, with Perfexion, both treating a patient and planning for that patient take more time. On top of that, Perfexion lacks what's called onboard imaging, same-day imaging, and frameless treatments — masks worn by the patient. What that means is that Esprit, which is the newest system, does provide these clinical capabilities: same-day onboard imaging, treatments without masks, quicker treatment times, and planning that's much faster. As a result, patient throughput — the number of patients — can go up dramatically. Within that same 8-hour window, you're now able to treat a substantial number of patients beyond what Perfexion ever allowed; it's also considerably simpler and more comfortable for the patient. Frequently, older patients simply cannot remain motionless for very long. With Esprit, though, because the treatment takes far less time, you'll see a growing number of patients being placed on Esprit.

Tony Kamin

analyst
#12

All right. On the international side, you've clearly made quite a few moves heading south into Latin America. Is the company exploring other regions globally? For instance, are you considering Europe, or any other place around the world?

Ray Stachowiak

executive
#13

Yes, that's correct. We have examined possibilities in Europe, and we have examined possibilities — and are currently examining possibilities — in Asia too.

Tony Kamin

analyst
#14

Great. And one last thing from me, I suppose — a question and a comment rolled into one. Ray, I'm aware of how long you've held shares. In fact, I believe my own first purchase of AMS stock was back in 2002, but just to verify what my own intuition is telling me, I've got a 20-year monthly chart of the stock right here in front of me. And honestly, from October of '07 onward — that's nearly 16 years now — the stock has simply been stuck in an extremely narrow band. According to what I have, a 20-year moving average puts the typical share price across those 20 years at $2.53. So here we are, right at that 20-year level. And I genuinely do appreciate — I truly believe you folks are headed in the right direction with every initiative you're pursuing and this far more aggressive posture; but the shares have, I think, sent a very clear signal, and it ought to be clear to the Board as well, that it's likely time to adopt something more directly hands-on and essentially try to take charge of your own future, given the stock trades at a discount to a $3.52 book and has, once again, gone nowhere for 17 years; so there are steps available to you. A buyback is one obvious option, and I think that would be genuinely beneficial — when companies repurchase shares, those shares tend to trade better generally once such programs are established amid an undervaluation like the one here. Other possibilities I think you could obviously examine — the stock traded at higher levels prior to 2007, back when a dividend existed. Whether it takes the form of cash paid out or shares issued as a stock dividend, that would truly be — speaking as somebody who has clearly held stock and backed this company for a very long stretch, showing as much patience as a person possibly could, my view is that now is the time for us to take a more active, involved approach when it comes to confronting the stubborn problem of our shares trading below what they're worth.

Ray Stachowiak

executive
#15

Tony, that's an excellent point, and I appreciate you bringing it up. There's only so much I can say regarding how our share price has performed across the past 15 or 20 years. My focus tends to be on the more recent period, yet as you noted, it has stayed within a fairly consistent band. When I came into the company on a fuller basis roughly three years back, the executive management team and the Board of Directors, I believe, did take a hard look. Drawing on my 22 years of experience leading companies as a CEO, we examined many different strategic paths available to the company and how we could best create value for our shareholders. And across the past two or three years, following the renegotiation of our debt, we built up our cash balances; our current view — though I continue to welcome other thoughts and ideas — is that putting money into the projects sitting in our pipeline represents the finest use of our capital, the finest return, and the finest method of building shareholder value. There's not much I'm able to disclose regarding that pipeline. The anticipated returns on those investments also can't be discussed. However, looking at where we stand right now, in essentially every quarter from here on out, radiation oncology will be an area where we put money to work. We're making upgrades at these locations. New business is coming in, and we're putting in new equipment. I've frequently mentioned the cash balances along with the $7 million line of credit available to us, which could be drawn on further, to put as much as $100 million into capital equipment. Just 1 or 2 proton beam deals would be enough to consume a meaningful share of those funds; and the Board's present view, as well as that of the executive management team, is that deploying that capital toward the anticipated returns from the opportunities sitting in our pipeline represents its best use.

Tony Kamin

analyst
#16

Okay, absolutely. That said, perhaps a program issuing dividends in stock form might draw fresh investors toward the equity, and aside from minor administrative expenses, it wouldn't actually use up your cash. So it could be worth considering.

Ray Stachowiak

executive
#17

We'll give that some thought. Such suggestions and perspectives are welcome to us, alright? That will always be the case; and Tony, regarding your initial inquiry, I'd like to revisit it. My response should be unambiguous. You wanted to know whether opportunities involving proton beams exist within our pipeline. Going deep into specifics makes me reluctant, and I brought up the additional offerings we provide, such as MR/LINACs, which are indeed part of our pipeline. I also wish to affirm that proton beams likewise appear in our pipeline, no question about it.

Tony Kamin

analyst
#18

Yeah, if you were able to land another deal along the lines of Orlando, I believe that would be transformational. It would simply shine an entirely new light on how undervalued this company is. So I wish you the best of luck with that, and thanks for taking my questions.

Ray Stachowiak

executive
#19

Thanks, Tony.

Harry Long

analyst
#20

Alright, I've got a handful of things I could ask, but I'll limit myself to just 1 or 2 so that others can have a chance to ask theirs and I can rejoin the queue afterward. So I'll keep this really brief. Regarding Esprit, tell me if I'm mistaken, but based on what you've filed, it seems the proton beam therapy business is generating roughly — is it somewhere around $10 million in yearly revenue, or have I got that wrong?

Ray Stachowiak

executive
#21

No, that's roughly correct.

Harry Long

analyst
#22

Alright. So I haven't really seen it separated out when it comes to cash flow from operations, but what I figure is that out of your $7 million or $8 million in cash flow — it depends on how you're annualizing — that could be accounting for somewhere between $2.7 million and $4 million of that cash flow. Am I way off? Or could we get a bit more granularity on the actual cash flow from operations that was generated there?

Ray Stachowiak

executive
#23

Tony, I think that's a pretty detail-oriented question, and we're probably hesitant to get specific about it.

Harry Long

analyst
#24

But suppose my estimate falls between $2.7 million and $4 million — does that make me crazy?

Ray Stachowiak

executive
#25

Most likely, you are not crazy.

Harry Long

analyst
#26

Okay, got it. Then the next thing I wanted to ask about was future contracts and what your approach will be for structuring them. And just to be clear, I'm using this term in a casual way, I might not have the correct accounting label, but would it be inaccurate for me to say that it seems like the removal costs tied to certain Gamma Knife devices, that, that gives rise to a contingent liability for removal that might end up being material, as you mentioned in your filings? I'm not sure whether it would actually be a contingent liability.

Ray Stachowiak

executive
#27

Yes; I suppose it is a possible contingent liability. However, we have, in the past, managed to handle that possibility, that contingency, by doing a very good job of upgrading the technology our clients use in return for extending the length of the agreement, or by carrying out reloads of the Cobalt-60 source at our Gamma Knife sites, which also lengthens the agreement. And as an example, the announcement this morning regarding our agreement with Methodist Hospital in San Antonio, that is a relationship that has lasted more than 25 years, dating back to 1998. So we have managed to handle that possible risk.

Harry Long

analyst
#28

So I suppose what I'm asking is, looking ahead — particularly when it comes to the Gamma Knife units or linear accelerators, and so on — do you folks intend to give clients an incentive to possibly remain with you by making them cover the removal costs should they decide against renewing? Or, in agreements that are right now being carried out or being thought about as we move forward, for any newly installed units of any of these devices, would those removal costs — if, say, that takes place 10 or 20 years down the road — fall on the company, or on the hospital system, or on the medical center?

Ray Stachowiak

executive
#29

Yes, that's the answer. This is something we are — it is under consideration and is receiving a great deal of consideration.

Harry Long

analyst
#30

Also, I'll rejoin the line so others get their chance, but I only wanted to add emphasis to what Tony said. A cash dividend from this company, in my view, would be outstanding. And if someone considered the Henry Singleton study of Teledyne, examining dividend stock buybacks and so forth, I believe the company can recognize that when you attempt to weigh two distinct returns on capital, plainly the return on capital from the company redeploying its own shares at 2x cash flow comes to roughly 45% to 50%, depending on one's assumptions about maintenance CapEx. So if we examine that capital allocation against the capital allocation behind, say, a new proton beam therapy device, which potentially would yield a return on total capital, a return on assets somewhere between 7% and 12.5% under a pessimistic or an optimistic scenario. It appears the company's own shares, while trading at under 2x cash flow on backs out to net cash, might constitute the very best — the capital allocation decision this company could make; and a dividend, I believe, if the company paid out a substantial portion of its cash flow as a dividend, I believe the stock could climb 400% to 700% as we have discussed. So — and I apologize, I owe you guys a white paper, but I'm going to rejoin the line. The cash flow from operations keeps being spectacular for the company, and I wanted to offer you all my compliments on some great work.

Ray Stachowiak

executive
#31

Thank you, Harry.

Analyst

analyst
#32

I'm someone who has some interest on a partial basis in putting money into your excellent business. That said, I've got a handful of things I'd like to ask, and they also center on the cash flow. Whenever you mention that a certain piece is restricted cash, which piece would that be?

Ray Stachowiak

executive
#33

Craig, I'm going to turn this over to you. From what I understand, a limited quantity of our cash is restricted.

Craig Tagawa

executive
#34

Because of the arrangement we have through GK Financing, that amount is limited. I believe it comes to roughly $50,000, with a small portion tied to terms, and then there is also a small piece related to our Fifth Third finance agreement.

Analyst

analyst
#35

Okay, so regarding that variable interest rate you're paying — what's the debt amount that applies to?

Ray Stachowiak

executive
#36

I'd put it at roughly 90% of the debt we carry that bears interest sitting at a variable rate. With Fifth Third Bank, every bit of what we owe them is variable — that's 100% — and whatever's left on a fixed basis is held with DFC.

Analyst

analyst
#37

Questioner: All right. Is there any way at all for you to tackle this particular matter?

Ray Stachowiak

executive
#38

Indeed. We have discussed protecting ourselves against what we owe and against movements in interest rates. Our view was that going with a floating rate was the optimal choice. In retrospect, one might cast doubt on that. Yet at the same time — I suppose the leadership group here leans somewhat toward taking risks and acting like entrepreneurs. That risk is something we are prepared to accept.

Analyst

analyst
#39

Now, regarding expansion. Yeah, I caught what the first speaker said about how the stock has been fairly flat. I checked the period running from 1987 up to today, and sure, you weren't around back in 1987; but what should we be expecting? What's being done in a different way when it comes to growing, or when it comes to dividends? How do you see things overall? Are you growing anticipated profitability extremely quickly? Or do you plan on giving shareholders dividends as their reward? What — could you share a bit more detail regarding your approach?

Ray Stachowiak

executive
#40

What we're doing right now is putting to work whatever capital is on hand for us. During the past several years, we've reworked our debt structure. We now hold a genuine banking connection with Fifth Third Bank, and we're quite confident that growing that connection will be possible; we've broadened what we offer, our range of products. Previously we supplied Gamma Knives plus had 1 proton beam system. Like I said before, we've widened our scope into every kind of radiation oncology device, linear accelerators, MR/LINACs, and proton beam systems, now even more robust than previously. Our sales and marketing operation used to be tiny. What we did for sales and marketing came largely through word of mouth, through the standing of the company's founder, Dr. Ernest Bates, who is still serving on our Board. And Peter, along with his team, has significantly built upon that work. Plus we've put plenty of resources into our sales and marketing group across the last 12 months. When it comes to radiation oncology equipment, lead times are lengthy, the sales cycle takes quite a while; and even after an agreement gets signed, the installation phase may be considerable too. Therefore, a certain amount of time will be needed before those revenue streams begin and gain momentum for our company. For the patient, long-term oriented investor, our stock ought to be appealing. When it comes to our stock — without question, it is undervalued. I'll state that I have personally been an investor who succeeded. That I can say without any hesitation. Our stock is undervalued; and our way of doing things is to allow the returns we can produce to show and be demonstrated. That hasn't happened yet. It's somewhat regrettable that the accounting and finance data submitted to the SEC, which gets disclosed to investors, is historical by nature; and that's too bad, since we have a bright future. Each revenue stream we bring on will support and aid our growth and our profitability going forward; and we've also broadened our business models so they now cover our owned and operated centers. That's been done by us internationally. Yet, as I said earlier during this conversation, we're growing that business model inside the domestic market. And beyond just the United States and to some degree South America, we're also examining various geographical markets; we've moved into Mexico. And like I noted earlier on today's call, we're reviewing opportunities in Europe as well as in Asia. Our pipeline holds plenty of possibilities. With the third order we've booked this year—I realize that isn't a large number—the sales pipeline remains quite robust. And a sales process needs a certain amount of time to run its course.

Analyst

analyst
#41

Alright, I really appreciate it. So, from what I gather, nothing is being set aside for the shareholder right now, meaning there's no invitation for shareholders to share in this earnings growth by receiving dividends from the stock — is that correct? That's essentially what you're telling us?

Ray Stachowiak

executive
#42

Not at this point — what I mean is, I want to keep an open mind, and I'm consistently receptive to suggestions and perspectives, everyone.

Ray Stachowiak

executive
#43

Alright, Luis, thanks for asking that. I can see how that would give an investor a lot of confidence.

Harry Long

analyst
#44

As things stand, with the contracts you have in place today, and maybe regarding the per-use side — and I mean specifically those per-use contracts involving medical centers and hospitals — they aren't similar to anything down in South America, where you could be running the operation on your own. So at present, when working with a hospital or a medical center, if there's a bad debt expense, or a patient fails to pay, whose responsibility would that be? Would that fall on you folks, or on the hospital?

Ray Stachowiak

executive
#45

In a fee per use structure, that expense falls on the hospital.

Harry Long

analyst
#46

So it seems like the existing model could deliver some pretty meaningful upside, even if it costs you somewhat upfront on margin? Then later on, it appears you capture that cash flow provided the patient stays on a machine for the procedure?

Ray Stachowiak

executive
#47

Correct. Should the patient's insurer run into trouble covering the treatment or procedure, that burden falls on the hospital system rather than American Shared when those kinds of arrangements are in place.

Harry Long

analyst
#48

Understood. That’s quite compelling. My next item concerns how things are handled. I value that the leadership group welcomes suggestions, including those raised by earlier speakers regarding dividends. Regarding how things are handled, though, would the leadership group be willing to set up a special committee of the Board of Directors to look into a possible dividend? To put it another way, as a concrete step, a special committee wouldn’t obligate you to take any action, yet it would give the Board a way to examine that capital allocation choice. Would the company’s leadership back forming such a committee?

Ray Stachowiak

executive
#49

Harry, I believe we welcome any and all thoughts and ideas, so I’d say that concept is very possible and we’re open to it.

Harry Long

analyst
#50

To be more precise, would management at the company ask the Board of Directors to put together a committee like that?

Ray Stachowiak

executive
#51

I believe we would need to look into it on our own somewhat prior to bringing it before the Board, and additional information would be welcome.

Harry Long

analyst
#52

I'd like to connect a few of these points, and you realize that both you and I are attempting this — my real aim here is to help everyone else listening. One thing I asked about, and I believe you can tell where this is headed, is what the cash flow looks like from the proton beam therapy systems. I get that you'd rather not disclose a figure for cash flow from operations. But a shareholder can hardly grasp what the true cash return on capital is for a new proton beam therapy device without knowing how much cash the existing system produces. And if we're on the same page that a new machine runs roughly $20 million, more or less, then knowing that cash flow matters — even supposing it reached $4 million, as you're aware, $4 million on 20%, that's a 20% return on total capital, or if it were nearer $2 million, a 10% return on total, just so the listeners understand, compared with your own shares, which if we agree trade at about 2x cash flow, depending on CapEx, amount to a 40% to 50% return on capital; so I suppose if we all accept that best practices mean weighing potential uses of capital and that management's top strategic duty is essentially to measure and then select the highest return on capital for the capital sitting on the company's balance sheet, I simply believe this gives shareholders a way to judge how you're making capital allocation decisions. So I tell people the devil is in the details, but salvation is there too. And if in upcoming quarterly releases we could receive somewhat more granular detail on that cash flow from operations from proton beam therapy, I think that would then open the conversation with your broader shareholder base regarding the competitive return on capital, the contest between proton beam therapy and share repurchases and dividends. So I just believe it's hugely important for the company to be more granular on that, since absent it, we truly aren't having a genuine discussion about competitive capital allocation decisions, if that makes any sense.

Ray Stachowiak

executive
#53

Well, I welcome thoughts and ideas, Harry, and I want to reaffirm to all our listeners that if anyone's interests line up with our shareholders, that person would be me. I hold a substantial ownership stake in the company personally. And I've arranged my compensation to take the form of company ownership as much as possible. And I — my goal is to boost our company's shareholder value in the best way I can. And I'd be careless not to mention that I welcome any thoughts and ideas for doing so. I want to raise our shareholders' value, and our stock is undervalued at present.

Harry Long

analyst
#54

All right, and on that subject, sirs, I saw that the stake you two hold comes to roughly 20% of the business, and perhaps slightly higher at this point, it might be — would you say it's around 20%?

Ray Stachowiak

executive
#55

That's roughly correct.

Harry Long

analyst
#56

Then for my second question — is there anything stopping investors who aren't part of management from reaching 20% in the same manner that you can? And it's possible I'm mistaken here, since this may have been a long time back. Maybe I'm correct — I recall a poison pill provision from years ago. Whether it lapsed, I have no idea. As things stand right now, what limits exist on how much stock outside investors — those who aren't the CEO, Chairman, or CFO — are permitted to own in this company?

Ray Stachowiak

executive
#57

Harry, that's something I can't answer, and I also don't think anyone on our present management team could answer it without looking it up, sitting here today.

Harry Long

analyst
#58

Given that you're sitting at 20%, and since all of you carry a sterling reputation for excellent ethics and fair dealing, I'd like to ask for something. It's my hope that you would back the idea that, if we're all in agreement that we trust in you and might each want to grow our holdings in the business — particularly if the team were receptive to something like dividends — then, since you're at 20%, I hope you would now put in place — and if any exist, I hope a special committee would be formed, if there are restrictions that would keep other shareholders from having the same ability to go up to 20% that you have right now. So I get it if some limitation applies to you and to everybody else, but my hope is that there is — the company has a process and a structure through which any shareholder could reach your present ownership level without setting off a poison pill provision. To me, that's simply basic fairness, something we could all get behind.

Ray Stachowiak

executive
#59

Harry, that would be a very interesting scenario to pursue.

Harry Long

analyst
#60

Got it, got it. Then I had one more thing I wanted to ask. Do all of us — I mean, I believe everyone here would say the company trades, prior to capex, at about 2x cash flow. Is that something we're all on the same page about on this call?

Ray Stachowiak

executive
#61

More or less, that sounds about right.

Harry Long

analyst
#62

So, circling back to compensation, when I'm examining in...

Ray Stachowiak

executive
#63

Harry, before we turn to the next question, just to make the figures clear — what comes to mind is a market valuation of $16 million a year, or $16 million, with EBITDA of about $8 million a year, meaning 2x.

Harry Long

analyst
#64

There's no disagreement from me at all; in fact, when you look at enterprise value, the figure would likely come in slightly under $16 million, since there's net excess cash sitting on the balance sheet. Put another way, I completely share your view, and I suspect the actual numbers are a touch better than 2x cash flow. So here's what I'd ask: would you gentlemen concur that, when I look at the roughly 2.7 figure in terms of <<inaudible>>, with part of the pricing sitting near 2.8, 2.7?

Ray Stachowiak

executive
#65

Harry, your connection is dropping out on us.

Harry Long

analyst
#66

My apologies. What I was getting at is whether we're all on the same page that a portion of these — the shares tied to management compensation — can be exercised at roughly, if I recall, about 2.78? Is that right?

Ray Stachowiak

executive
#67

Harry, that's one more item where I can't give you an answer off the top of my head.

Harry Long

analyst
#68

All right. Bob, since you're our CFO, I imagine those figures are right there with you. When shares get issued as part of management compensation and then exercised, is the figure somewhere near 2.78?

Bob Hiatt

executive
#69

Yes, that's definitely within the ballpark. The — correct. In our Q, we mention it — there is a footnote covering exactly that.

Harry Long

analyst
#70

All right, so let me explain where I'm headed with this. I believe everyone would concur that all of you are paid quite fairly. If you achieve specific targets and perform tremendously on cash flow, I doubt any of us would object to all of you getting greater cash pay. Still, I do believe that certain shareholders reviewing this — investors who deeply admire everything all of you are achieving — if we currently, if we all accept that this company trades at roughly 2x cash flow, then I think we'd unanimously agree about the message it conveys when management grants itself shares potentially exercisable at approximately 2x cash flow, and at what all of us consider to be below the company's tangible book value. So when you've got a strike price under the tangible book value of the company and near 2x cash flow, you gentlemen are a phenomenal management team. And I believe you recognize deep down that this appears improper to any intelligent investor examining this company. And I think it establishes the wrong impression when management awards itself shares exercisable at roughly 2x cash flow while providing no cash dividend to shareholders, many of whom, as plenty of callers have noted for decades — more than a decade — have gotten no return, which I understand stems from prior management, entirely unrelated to the current team. But I'd urge you, gentlemen, just as we discuss capital allocation choices, of buybacks and dividends compared with purchasing new equipment, that you'd likewise concur that if all of you could be paid more, nobody would object to all of you getting greater cash pay. Or should you prefer the shares, set the strike price at 6 or 7x earnings, which matches the steady state of cash flow typically received in the stock market. Yet having shares exercisable at 2x cash flow — I'm certain when you gentlemen think it over, if you reflect on it a bit further, I'm confident you'll see it my way, since you're intelligent and I'm correct.

Ray Stachowiak

executive
#71

Well, Harry, the best I can tell you is that we haven't paid our employees heavily through stock options.

Harry Long

analyst
#72

The standard gets established by leadership, and you are owed — let me say this plainly, you are owed greater cash pay. I have no objection to higher cash compensation. But both of us realize, and surely this plan was drafted well before you took the CEO role, that it's an easy thing to miss, yet an exercise price sitting under tangible book value simply cannot be allowed. You're aware of it, I'm aware of it. This has to end. I'm behind you all receiving bigger cash pay, and you aren't being paid in some outrageous manner, but receiving shares priced at an exercise level of 2x cash flow and beneath tangible book, all while no cash dividend goes to shareholders, is simply unacceptable; and I'm certain this was arranged without your awareness by certain compensation consultants and in some way slipped past everyone. So I don't fault you personally, but this has to end. That's everything from me today. And I did want to praise you for the incredible cash flow; and on a few of these matters, we can argue about things such as the shareholder dividend, but having an exercise price under tangible book is truly beyond the pale, it's simply unheard of.

Ray Stachowiak

executive
#73

Well, I'd say our share price trading under or nearly under tangible book value is under tangible book value.

Harry Long

analyst
#74

Fine. You are extremely intelligent, yet intelligence alone doesn't guarantee correctness. Plus, this is something you ought not to battle anybody over. You need to quit setting an exercise price at 2x cash flow and under tangible book, correct; that's simply unprecedented. Also, you ought to receive additional cash compensation. I'd like you to get guaranteed cash compensation. However, obtaining shares exercisable beneath tangible book, that isn't defensible. It simply isn't, particularly when shareholders aren't receiving a cash dividend. That's unacceptable.

Ray Stachowiak

executive
#75

Noted, Harry.

Ray Stachowiak

executive
#76

Thanks, Allison. I appreciate all of you being here with us today. We're enthusiastic about the higher levels of activity we're seeing at AMS, and we can't wait to share what we've been developing when the right moment comes. Keep an eye out. The next time we'll talk with you is on our call for the third quarter, which takes place in mid-November. If anything comes up before that, don't hesitate to reach out to us directly. In the meantime, take care, stay safe, and enjoy your evening. Goodbye.

Operator

operator
#77

That wraps up our call. We appreciate everyone joining us for today's presentation, and at this point you're free to leave the line.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.